DEFINITIVE CONTRACT
Active75F40126C00071
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$353K
obligated · signed 2 months ago
BAA FY26C1CP53: ADVANCING INTEGRATION OF IN VITRO TOPICAL PRODUCT CHARACTERIZATION AND SKIN PERMEATION DATA
Performance timeline
Start
Sep 30, 2026
End
Sep 29, 2029
with all options
Loading status
Estimated start: Sep 29, 2028
CERTARA UK LIMITED
Contract 75F40126C00071
UEI
WWBMG5E7KT69
Parent Company
CERTARA UK LIMITED
Capabilities & Certifications
Headquarters Location
Current Obligation
$352,968
Base + Exercised Options
$352,968
Total Ceiling Value
$1,083,957
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.